Physician profile
Michael Goebel
NPI 1366607749
$31,220.83
in general payments reported to CMS, 2019-2025
35 companies · $3,703 in 2025
The $3,703 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,666 · 2020: $734 · 2021: $2,668 · 2022: $6,338 · 2023: $6,238 · 2024: $5,874 · 2025: $3,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $4,229 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,375.00 |
| Food and Beverage | $4,229.01 |
| Education | $210.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,452.45 | 2019-2025 | |
| Allergan, INC. | $4,391.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,273.28 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $984.43 | 2019-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $777.36 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $489.89 | 2019-2025 | Entyvio |
| Pfizer INC. | $343.54 | 2019-2025 | |
| Boston Scientific Corporation | $295.87 | 2019-2021 | |
| Gilead Sciences, INC. | $236.82 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $232.78 | 2020-2023 | |
| Qol Medical, LLC | $225.70 | 2019-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $198.08 | 2020-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $149.82 | 2021-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $143.14 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $141.24 | 2022-2025 | Ibsrela |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $136.09 | 2021-2023 | Injectafer |
| Janssen Scientific Affairs, LLC | $117.37 | 2019-2021 | |
| Madrigal Pharmaceuticals | $86.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $82.26 | 2025 | |
| Amgen INC. | $77.48 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $48.33 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $46.12 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $43.62 | 2020-2024 | Suflave |
| Redhill Biopharma INC. | $41.50 | 2020-2021 | |
| Evoke Pharma, INC. | $39.90 | 2024 | |
| Lilly USA, LLC | $32.55 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $23.59 | 2021-2022 | |
| Medtronic, INC. | $21.56 | 2022 | |
| Endogastric Solutions, INC | $17.15 | 2022 | |
| Shire North American Group INC | $14.27 | 2019 | |
| Fresenius Kabi USA, LLC | $14.23 | 2023 | Idacio |
| Alfasigma USA, INC. | $12.75 | 2022 | |
| Echosens North America, INC. | $11.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 | |
| Phathom Pharmaceuticals, INC. | $8.16 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.